SAN DIEGO, June 19, 2014 – Profil Institute for Clinical Research, Inc., an early phase clinical research organization focused on diabetes and obesity, announced today presentations by CEO Dr. Marcus Hompesch at the Best of ADA Middle East Conference taking place in Dubai, June 26-27.
The Best of ADA Middle East is a conference hosted by the American Diabetes Association (ADA). A committee works with the Middle East life science industry to identify topics of interest from the ADA’s Scientific Sessions’ abstracts. Speakers of those particular abstracts are then invited to present in Dubai. Dr. Hompesch is an invited speaker and will present “The Need for a Better Basal Insulin” and “Biosimilars – Opportunities and Challenges.”
More information about conference presentations by Profil Institute scientists is available on the company’s website at www.profilinstitute.com/news-events/conferences/.
About Profil® Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization focused on diabetes and obesity. The company is renowned as a center of excellence for metabolic clinical research and development based on its scientific expertise, depth of services, and research methodologies. Operational since 2004, Profil Institute is a trusted partner and service provider for its clients from small virtual companies to large pharma and drug discovery companies, as well as academic centers, throughout the Americas, Europe and Asia.
Profil Institute works with clients to design and execute first-in-human, proof of mechanism clinical research for metabolic drug and device candidates. To date, Profil Institute has completed more than 200 phase I-IIa diabetes and obesity clinical studies, involving every clinically relevant diabetes drug class and a wide array of medical devices. In addition to clinical research, Profil Institute provides early phase clinical development services and consulting, including the design of strategic clinical development plans and management of regulatory affairs. For more information visit www.profilinstitute.com.
For further information, please contact: